Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Apogee Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Apogee Therapeutics, Inc.’s stock price such as:

• Apogee Therapeutics, Inc.’s current stock price and volume
• Why Apogee Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for APGE from analysts
• APGE’s stock price momentum as measured by its relative strength

About Apogee Therapeutics, Inc. (APGE)

Before we jump into Apogee Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Want to learn more about Apogee Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Apogee Therapeutics, Inc..

What Caused Apogee Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 30, 2026, there were 0 analysts who downgraded Apogee Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Apogee Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Apogee Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Apogee Therapeutics, Inc. (APGE) by visiting AAII Stock Evaluator.

Relative Price Strength of Apogee Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 30, 2026, Apogee Therapeutics, Inc. has a weighted four-quarter relative price strength of 15.99%, which translates to a Momentum Score of 87 and is considered to be Very Strong.

Want to learn more about how Apogee Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Apogee Therapeutics, Inc. Stock Price: Bottom Line

As of May 1, 2026, Apogee Therapeutics, Inc.’s stock price is $82.470, which is down 0.51% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Apogee Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.